Sunday Jul 20, 2025
NEWSLETTER
www.israelhayom.com
  • Home
  • News
    • Israel
    • Israel at War
    • Middle East
    • United States
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
  • In Memoriam
www.israelhayom.com
  • Home
  • News
    • Israel
    • Israel at War
    • Middle East
    • United States
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
  • In Memoriam
www.israelhayom.com
Home Economy

Teva settles with Oklahoma for $85 million in opioid case

Funds to be used to fight the opioid crisis in Oklahoma, says state Attorney General Mike Hunter. Under terms of agreement, Teva does not admit any wrongdoing.

by  Associated Press and Israel Hayom Staff
Published on  05-27-2019 12:18
Last modified: 09-23-2019 13:32
Teva settles with Oklahoma for $85 million in opioid caseReuters/Baz Ratner

FILE PHOTO: A building belonging to generic drug producer Teva is seen in Jerusalem March 23, 2010. | Photo: Reuters/Baz Ratner

Share on FacebookShare on Twitter

One of the drugmakers named in Oklahoma's lawsuit over the opioid crisis has agreed to a settlement in which it will pay the state $85 million.

Israeli-owned Teva Pharmaceuticals and Oklahoma Attorney General Mike Hunter both announced the settlement on Sunday in separate statements. Teva, its related affiliates, Johnson & Johnson and several of its subsidiaries were set to go to trial Tuesday in Norman, Oklahoma.

Hunter said the case against Johnson & Johnson will proceed on schedule.

He also said that the funds from the settlement with Teva will be used to fight the opioid crisis in Oklahoma.

Teva did not admit any wrongdoing under the settlement.

Earlier this year, Oklahoma settled with OxyContin-maker Purdue Pharma for $270 million.

Tags: Oklahomaopioid crisisopioidspharmaTevaTeva Pharmaceuticals

Related Posts

'Sell kidney, keep Bitcoin': Who supports Michael Saylor's crypto visionREUTERS/Dado Ruvic/; AP Photo/Rebecca Blackwell

'Sell kidney, keep Bitcoin': Who supports Michael Saylor's crypto vision

by Erez Linn

From Tesla to MetaPlanet, Strategy CEO's Bitcoin playbook is changing the corporate game. Who’s next?

Netflix earnings: 46% profit surge amid subscriber growthREUTERS/Patrick T. Fallon

Netflix earnings: 46% profit surge amid subscriber growth

by Erez Linn

Netflix exceeded second-quarter expectations and boosted its annual revenue projections, driven by subscriber growth, price hikes, and advertising momentum, with...

Dow climbs 229 points as robust earnings and economic data fuel investor optimismAFP / Angela Weiss

Dow climbs 229 points as robust earnings and economic data fuel investor optimism

by Erez Linn

Corporate results exceed expectations while retail sales and employment figures reinforce economic strength

Menu

Analysis 

Archaeology

Blogpost

Business & Finance

Culture

Exclusive

Explainer

Environment

 

Features

Health

In Brief

Jewish World

Judea and Samaria

Lifestyle

Cyber & Internet

Sports

 

Diplomacy 

Iran & The Gulf

Gaza Strip

Politics

Shopping

Terms of use

Privacy Policy

Submissions

Contact Us

About Us

The first issue of Israel Hayom appeared on July 30, 2007. Israel Hayom was founded on the belief that the Israeli public deserves better, more balanced and more accurate journalism. Journalism that speaks, not shouts. Journalism of a different kind. And free of charge.

All rights reserved to Israel Hayom

Hosted by sPD.co.il

  • Home
  • News
    • Israel at War
    • Israel
    • United States
    • Middle East
    • Sports
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
    • Environment & Wildlife
    • Health & Wellness
  • In Memoriam
  • Subscribe to Newsletter
  • Submit your opinion
  • Terms and conditions

All rights reserved to Israel Hayom

Hosted by sPD.co.il

Newsletter

[contact-form-7 id=”508379″ html_id=”isrh_form_Newsletter_en” title=”newsletter_subscribe”]

  • Home
  • News
    • Israel at War
    • Israel
    • United States
    • Middle East
    • Sports
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
    • Environment & Wildlife
    • Health & Wellness
  • In Memoriam
  • Subscribe to Newsletter
  • Submit your opinion
  • Terms and conditions

All rights reserved to Israel Hayom

Hosted by sPD.co.il